Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies
Genes · 2023
DOI: 10.3390/genes14122217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2023. Verfasst von Shabnam Nohesara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA. Hauptthemen laut MEDLINE: Major Depressive Disorder, Microbiota, Gastrointestinal Microbiome, Probiotics. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Major depressive disorder (MDD) is a complex disorder and a leading cause of disability in 280 million people worldwide. Many environmental factors, such as microbes, drugs, and diet, are involved in the pathogenesis of depressive disorders. However, the underlying mechanisms of depression are complex and include the interaction of genetics with epigenetics and the host immune system. Modifications of the gut microbiome and its metabolites influence stress-related responses and social behavior in patients with depressive disorders by modulating the maturation of immune cells and neurogenesis in the brain mediated by epigenetic modifications. Here, we discuss the potential roles of a leaky gut in the development of depressive disorders via changes in gut microbiota-derived metabolites with epigenetic effects. Next, we will deliberate how altering the gut microbiome composition contributes to the development of depressive disorders via epigenetic alterations. In particular, we focus on how microbiota-derived metabolites such as butyrate as an epigenetic modifier, probiotics, maternal diet, polyphenols, drugs (e.g., antipsychotics, antidepressants, and antibiotics), and fecal microbiota transplantation could positively alleviate depressive-like behaviors by modulating the epigenetic landscape. Finally, we will discuss challenges associated with recent therapeutic approaches for depressive disorders via microbiome-related epigenetic shifts, as well as opportunities to tackle such problems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
- Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boson, MA 02215, USA.
- Department of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
ORCID-Profile: Hamid Mostafavi Abdolmaleky, Jin-Rong Zhou, Sam Thiagalingam
Förderung
- NCI NIH HHS
- National Institute of Health
Zitieren
APA
Nohesara, S., Abdolmaleky, H. M., Zhou, J. R., & Thiagalingam, S. (2023). Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies. Genes. https://doi.org/10.3390/genes14122217
Vancouver
Nohesara S, Abdolmaleky HM, Zhou JR, Thiagalingam S. Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies. Genes. 2023. doi:10.3390/genes14122217
BibTeX
@article{Nohesara2023,
author = {Nohesara, Shabnam and Abdolmaleky, Hamid Mostafavi and Zhou, Jin-Rong and Thiagalingam, Sam},
title = {Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies},
journal = {Genes},
year = {2023},
doi = {10.3390/genes14122217}
}
EUVIMED